FOR US HEALTHCARE PROFESSIONALS

For the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis

AURYXIA provides the convenience of at-home dosing1

Based on the oral administration of AURYXIA:

  • No needles
  • No trips to infusion centers
  • Patients don’t have to leave the comfort of their own home

Dosing guidelines1

icon

Swallow whole
with meals

icon

Starting dose 1 tablet
3 times/day

icon

Monitor and adjust the dose as needed*

icon

Maximum dose
12 tablets daily

AURYXIA delivers: 210 mg of ferric iron per tablet1†

>1500 mg of ferric iron in 3 days1†

*Titrate the dose of AURYXIA as needed to achieve and maintain hemoglobin levels.
†Represents ferric iron delivered and not ferric iron absorbed. Calculation is based on 210 mg of ferric iron per tablet and the starting dose of 1 tablet 3 times/day with meals. In the clinical trial, patients required an average of 5 tablets per day to increase hemoglobin levels.

Oral drugs that cannot be taken at the same time as AURYXIA1

Be aware of the drug-to-drug interactions of AURYXIA before prescribing to patients

  • Doxycycline—Take at least 1 hour before AURYXIA
  • Ciprofloxacin—Take at least 2 hours before or after AURYXIA
  • For oral medications where a reduction in bioavailability would have a clinically significant effect, consider separation of timing of administration with AURYXIA

IMPORTANT SAFETY INFORMATION AND INDICATION

CONTRAINDICATION

AURYXIA® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis

WARNINGS AND PRECAUTIONS

  • Iron Overload: Increases in serum ferritin and transferrin saturation (TSAT) were observed in clinical trials with AURYXIA in patients with chronic kidney disease (CKD) on dialysis treated for hyperphosphatemia, which may lead to excessive elevations in iron stores. Assess iron parameters prior to initiating AURYXIA and monitor while on therapy. Patients receiving concomitant intravenous (IV) iron may require a reduction in dose or discontinuation of IV iron therapy
  • Risk of Overdosage in Children Due to Accidental Ingestion: Accidental ingestion and resulting overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Advise patients of the risks to children and to keep AURYXIA out of the reach of children

ADVERSE REACTIONS
The most common adverse reactions reported with AURYXIA in clinical trials were:

  • Iron Deficiency Anemia in CKD Not on Dialysis: Discolored feces (22%), diarrhea (21%), constipation (18%), nausea (10%), abdominal pain (5%) and hyperkalemia (5%)

SPECIFIC POPULATIONS

  • Pregnancy and Lactation: There are no available data on AURYXIA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. However, an overdose of iron in pregnant women may carry a risk for spontaneous abortion, gestational diabetes and fetal malformation. Data from rat studies have shown the transfer of iron into milk, hence, there is a possibility of infant exposure when AURYXIA is administered to a nursing woman

INDICATION

AURYXIA® (ferric citrate) is indicated for:

  • The treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis

To report suspected adverse reactions, contact Akebia Therapeutics, Inc. at 1-844-445-3799

Please see full Prescribing Information

REFERENCES

  1. AURYXIA® [Package Insert]. Cambridge, MA: Akebia Therapeutics, Inc.; 2021.
  2. Fishbane S, Block GA, Loram L, et al. Effects of ferric citrate in patients with nondialysis-dependent CKD and iron deficiency anemia. J Am Soc Nephrol. 2017; 28(6):1851-1858.
  3. Data on File 16, Akebia Therapeutics, Inc.
  4. Data on File 14, Akebia Therapeutics, Inc.